ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BioNTech and Moderna side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BioNTechModerna
studies on the registry125119
open to participants now3318
phase 3 studies under way92
reach primary completion within a year1116
programswith a study of their own in two years2316

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBioNTechModerna
Phase 1

BioNTech: 4 of its 23 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%

Moderna: 5 of its 16 programs at phase 1

  1. MRNA-1365phase 1
  2. MRNA-1469phase 1
  3. mRNA-1519phase 1
  4. MRNA-4106phase 1
  5. MRNA-4200phase 1
31%
Phase 265%31%
Phase 3

BioNTech: 3 of its 23 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%

Moderna: 3 of its 16 programs at phase 3

  1. mRNA-1345 respiratory syncytial virus vaccinephase 3
  2. MRNA-1018phase 3
  3. MRNA-1083phase 3
19%
Approved, new studies

BioNTech: 1 of its 23 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Moderna: 3 of its 16 programs at approved, new studies

  1. 2019-nCoV Vaccine mRNA-1273approved, new study
  2. MRNA-1283approved, new study
  3. mRNA-1010 influenza vaccineapproved, new study
19%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 12 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
Moderna9 readouts · 4 phase 3·

Moderna, Dec ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. mRNA-1010 influenza vaccineapproved, new study · Dec 7 · NCT07884175
  2. 2019-nCoV Vaccine mRNA-1273approved, new study · Dec 11 · NCT07863635
  3. MRNA-1283approved, new study · Dec 11 · NCT07863635

Moderna, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. MRNA-1018phase 3 · Jan 28 · NCT07496450
···

Moderna, May ’27: 1 program whose next study reaches primary completion

  1. Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189phase 2 · May 15 · NCT07478952
·

Moderna, Jul ’27: 1 program whose next study reaches primary completion

  1. MRNA-1365phase 1 · Jul 20 · NCT07764237

Moderna, Aug ’27: 2 programs whose next study reaches primary completion

  1. MRNA-4106phase 1 · Aug 3 · NCT06880549
  2. MRNA-4200phase 1 · Aug 3 · NCT06880549

Moderna, Sep ’27: 1 program whose next study reaches primary completion

  1. MRNA-1469phase 1 · Sep 30 · NCT07737717
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BioNTech

New programs 2

  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Moderna

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionBioNTechModerna
Influenza, Humanboth · compare here
COVID-19both · compare here

BioNTech in COVID-19: 1 program

  1. BNT162 Vaccineapproved, new study

Their studies: BioNTech’s studies of COVID-19 in search

Moderna in COVID-19: 3 programs

  1. MRNA-1083phase 3
  2. 2019-nCoV Vaccine mRNA-1273approved, new study
  3. MRNA-1283approved, new study

Their studies: Moderna’s studies of COVID-19 in search

Neoplasm Metastasisboth · compare here

BioNTech in Neoplasm Metastasis: 1 program

  1. trastuzumab pamirtecanphase 3

Their studies: BioNTech’s studies of Neoplasm Metastasis in search

Moderna in Neoplasm Metastasis: 2 programs

  1. MRNA-4106phase 1
  2. MRNA-4200phase 1

Their studies: Moderna’s studies of Neoplasm Metastasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: BioNTech 11 of 23 · Moderna 5 of 16 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.